While spliceosomal gene mutations were thought to be rare in de novo acute myeloid leukemia (AML) based on initial reported frequencies of 6.6% by Yoshida et al. (2011) and <5% in The Cancer Genome Atlas (The Cancer Genome Atlas Research Network 2013), subsequent analyses of elderly AML (>60-yr-old) cohorts revealed spliceosomal mutations in 20%–40% of such patients, the majority of which is SRSF2 mutations (Silva et al. 2015). Here, SRSF2 is linked to acute myeloid leukemia.